PMID- 37470209
OWN - NLM
STAT- MEDLINE
DCOM- 20230721
LR  - 20230724
IS  - 1096-9071 (Electronic)
IS  - 0146-6615 (Linking)
VI  - 95
IP  - 7
DP  - 2023 Jul
TI  - Oral azvudine for mild-to-moderate COVID-19 in high risk, nonhospitalized adults: 
      Results of a real-world study.
PG  - e28947
LID - 10.1002/jmv.28947 [doi]
AB  - Azvudine is recommended by Chinese health authorities for COVID-19 treatment but 
      has not been tested in real-world clinical studies. This study aimed to evaluate 
      the real-world effectiveness of Azvudine among COVID-19 nonhospitalized patients. 
      This was a retrospective cohort study, looking at nonhospitalized patients who 
      tested positive for SARS-CoV-2. Patients admitted between December 19, 2022 and 
      January 5, 2023 were included. Those who received Azvudine treatment were in the 
      Azvudine group, while those who received supportive treatment were the control 
      group. The primary outcome was the disease progression rate by Day 28. Secondary 
      outcomes were individual disease progression outcomes (death or COVID-19-related 
      hospitalization) and duration of fever. The safety outcomes were assessed based 
      on adverse events (AEs) overall, as well as AEs that were considered to be 
      related to the drug. A total of 804 patients with high risk for progression were 
      enrolled in our study. Among them, 317 (39.43%) received treatment with Azvudine. 
      Our study found that Azvudine could reduce the rate of disease progression, as 
      well as rate of COVID-19-related hospitalization in patients comparing the 
      control group. Furthermore, if taken within 3 days of the onset of symptoms, it 
      could also shorten the duration of fever. Despite a higher incidence of 
      drug-related AEs compared to supportive treatment, the majority of these were 
      mild. Azvudine has been found to be effective in reducing the rate of disease 
      progression of COVID-19, albeit with a slight increase in AEs.
CI  - (c) 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals 
      LLC.
FAU - Yang, Hui
AU  - Yang H
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - Wang, Zhaojian
AU  - Wang Z
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - Jiang, Chunguo
AU  - Jiang C
AD  - Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, 
      Beijing Institute of Respiratory Medicine, Capital Medical University, Beijing, 
      China.
FAU - Zhang, Yi
AU  - Zhang Y
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - Zhang, Ying
AU  - Zhang Y
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - Xu, Man
AU  - Xu M
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - Zhang, Yi
AU  - Zhang Y
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - Wang, Yushu
AU  - Wang Y
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - Liu, Xuefeng
AU  - Liu X
AUID- ORCID: 0000-0002-9922-9627
AD  - Departments of Pathology, Urology, and Radiation Oncology, The Ohio State 
      University, Columbus, Ohio, USA.
FAU - An, Zhuoling
AU  - An Z
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - Tong, Zhaohui
AU  - Tong Z
AUID- ORCID: 0000-0002-5341-6857
AD  - Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, 
      Beijing Institute of Respiratory Medicine, Capital Medical University, Beijing, 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
RN  - IJ2XP0ID0K (azvudine)
SB  - IM
MH  - Humans
MH  - Adult
MH  - *COVID-19
MH  - SARS-CoV-2
MH  - COVID-19 Drug Treatment
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Disease Progression
OTO - NOTNLM
OT  - Azvudine
OT  - COVID-19
OT  - effectiveness and safety
OT  - real-world study
EDAT- 2023/07/20 06:42
MHDA- 2023/07/21 06:42
CRDT- 2023/07/20 05:35
PHST- 2023/06/26 00:00 [revised]
PHST- 2023/05/06 00:00 [received]
PHST- 2023/06/27 00:00 [accepted]
PHST- 2023/07/21 06:42 [medline]
PHST- 2023/07/20 06:42 [pubmed]
PHST- 2023/07/20 05:35 [entrez]
AID - 10.1002/jmv.28947 [doi]
PST - ppublish
SO  - J Med Virol. 2023 Jul;95(7):e28947. doi: 10.1002/jmv.28947.